AVAV Underperforms Industry in the Past 6 Months: What Should You Do?

AeroVironment shares have fallen 30.6% over six months, underperforming its aerospace-defense equipment industry’s 12.1% decline, despite fiscal Q1 2027 revenue rising 6% year over year to $480.5 million and EPS increasing to $0.59 from $0.32. The company won a more-than-$50 million international LOCUST laser-system order, following a $464.8 million U.S. Army laser contract, but faces labor shortages and component-supply constraints that could pressure execution and margins. AVAV trades at 41.47x forward earnings versus the industry’s 33.59x, while its 4.04% ROE trails the 15.35% industry level; consensus forecasts fiscal 2027 EPS to decline 3.3%, supporting the article’s Sell stance.

Analysis

AVAV's key issue is not liquidity but earnings conversion: a premium multiple leaves little tolerance for program ramps that consume working capital, expedite components, or absorb fixed labor before volume materializes. The relevant next catalyst is whether management can demonstrate gross-margin progression and backlog-to-revenue conversion in the next one to two quarterly prints; revenue growth alone will not re-rate the shares. A further estimate reset would likely compress the multiple toward defense-equipment peers, creating downside over the next 1-3 months.

The directed-energy opportunity is strategically more valuable than the initial order size implies because export adoption can establish a recurring sustainment, software, and spares stream. However, international laser-defense sales have longer acceptance, export-control, and integration cycles than conventional drones; investors should not capitalize this as near-term high-margin revenue until delivery schedules and follow-on awards are disclosed. The more immediate second-order beneficiary is likely specialized defense electronics and subsystem capacity, where bottlenecks can confer pricing power rather than merely create industry-wide cost pressure.

AIR and ATRO are imperfect AVAV comparables: their relative strength may reflect aftermarket and commercial-aerospace exposure rather than superior exposure to autonomous systems. A short AVAV versus long ITA is cleaner than shorting against either peer, isolating company-level execution risk while retaining exposure to defense-budget resilience. Contrarian upside emerges if counter-UAS procurement shifts from prototypes to funded programs of record faster than expected; that would validate AVAV's differentiated product set and make a valuation-only short vulnerable to sharp contract-driven squeezes.

Falsification for the bearish relative view is a quarterly gross-margin expansion accompanied by raised full-year EPS guidance, or disclosed funded backlog sufficient to support the following fiscal year's growth without a material working-capital build. Conversely, any reduction in delivery assumptions, inventory build, or unfavorable mix commentary should be treated as confirmation that the current earnings recovery is being deferred rather than lost.

Key Decisions for Investors

• Maintain an underweight in AVAV for the next 1-3 months; add only on a post-earnings rally if management does not raise full-year EPS guidance. Target relative downside is multiple convergence from roughly 41x toward the defense-equipment peer range, with a stop on raised guidance plus clear gross-margin improvement.
• Implement a 3-6 month pair: short AVAV / long ITA, sized beta-neutral. This retains defense-spending exposure while monetizing AVAV-specific execution and valuation risk; reassess immediately if a material program-of-record award or export approval is announced.
• Do not chase AIR or ATRO solely as sympathy beneficiaries. Establish alerts for earnings revisions, supplier lead-time commentary, and margin guidance; a long position requires evidence that their gains are supported by improving free-cash-flow conversion rather than multiple expansion.
• For an upside hedge against a counter-UAS procurement acceleration, use a small defined-risk AVAV call spread expiring after the next earnings release rather than covering the core relative short outright. The hedge should be retained only while contract timing, export approvals, and production capacity remain unverified.